MedTrace Logo

Hypofractionated Radiosurgery for Localised Prostate Cancer (HYPOSTAT-III)

NCT06914544 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2026-04-29

No results posted yet for this study

Summary

Hypofractionated radiosurgery with 5 fractions is considered standard of care for localized prostate cancer. The investigators initiated this multicenter phase II prospective trial to analyse feasibility (toxicity) of hypofractionated radiosurgery with 3 fractions in patients with localised prostate cancer under the hypothesis that the ratio of patients with late GU and GI toxicity ≥ grade 2 after 1 year amounts to 8.4% and 1.3% and is significant lower than 16.4% and 5.7% currently.

Conditions

Interventions

RADIATION

Hypofractionated Radiosurgery

Image-guided stereotactic Linac based RT preferable with "dedicated radiosurgery system" such as CyberKnife

Sponsors & Collaborators

  • University of Luebeck

    collaborator OTHER

  • University Hospital Schleswig-Holstein

    lead OTHER

Principal Investigators

  • David Krug, MD · University Hospital Schleswig-Holstein

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-12-10
Primary Completion
2028-12-31
Completion
2029-12-31

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06914544 on ClinicalTrials.gov